drugset / Trial / NCT04947137

Development of a Normative Database for Rheumatoid Arthritis (RA) Imaging With Tc99m Tilmanocept

NCT04947137

Phase 2 Completed 134 enrolled Navidea Biopharmaceuticals
Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

This study will establish a normative database of Tilmanocept Uptake Values (TUVjoint) in healthy controls age-matched to the RA population.

Timeline

Start
2021-05-27
Primary completion
2022-01-21
Completion
2022-01-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Technetium Tc 99m Tilmanocept Diagnostic / imaging agent

Indications